Long-Term Maintenance of Certolizumab Pegol Safety and Efficacy, in Combination with Methotrexate and as Monotherapy, in Rheumatoid Arthritis Patients

INTRODUCTION: The safety and efficacy of certolizumab pegol (CZP) 400 mg every 4 weeks (Q4W) monotherapy (FAST4WARD/NCT00548834) and in combination with methotrexate (MTX) (014/NCT00544154) in active rheumatoid arthritis (RA) has been published previously. This report outlines final long-term outcom...

Descripción completa

Detalles Bibliográficos
Autores principales: Fleischmann, Roy, van Vollenhoven, Ronald F., Vencovský, Jiri, Alten, Rieke, Davies, Owen, Mountian, Irina, de Longueville, Marc, Carter, David, Choy, Ernest
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5443729/
https://www.ncbi.nlm.nih.gov/pubmed/28353191
http://dx.doi.org/10.1007/s40744-017-0060-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5443729/
https://www.ncbi.nlm.nih.gov/pubmed/28353191
http://dx.doi.org/10.1007/s40744-017-0060-8

Ejemplares similares